988
Participants
Start Date
May 31, 2009
Primary Completion Date
November 30, 2012
Study Completion Date
August 31, 2015
Ipilimumab
5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Placebo
Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Local Institution, Lima
Local Institution, Lima
Local Institution, Brussels
Local Institution, Buenos Aires
Local Institution, Vienna
Local Institution, Brussels
Local Institution, Buenos Aires
Local Institution, Budapest
Local Institution, Brussels
Local Institution, Caba
Local Institution, Capital Federal
Local Institution, Rosario
Local Institution, København Ø
Local Institution, Herlev
Local Institution, Heidelberg
Local Institution, Box Hill
Local Institution, Frankston
Local Institution, San Miguel de Tucumán
Local Institution, Odense C
Local Institution, Salzburg
Local Institution, La Rioja
Local Institution, Gyula
Local Institution, Kecskemét
Local Institution, Subiaco
Local Institution, Kaposvár
Local Institution, Aarhus
Local Institution, Roeselare
Local Institution, Aalborg
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College, New York
Local Institution, Marseille
Local Institution, Berlin
Va Pittsburgh Healthcare System, Pittsburgh
St. Luke'S Hospital & Health Network Laboratory, Bethlehem
Associates In Hematology & Oncology, P.C., Upland
Local Institution, Milan
Local Institution, Aguascalientes
The Bunting-Blaustein Cancer Research Building, Baltimore
Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick
Local Institution, Sondrio
Local Institution, Besançon
Edwards Comprehensive Cancer Center, Huntington
Raleigh Hematology Oncology Associates, Raleigh
Local Institution, Madrid
Musc Hollings Cancer Center, Charleston
Suburban Hematology-Oncology Associates, Pc, Lawrenceville
Local Institution, Haifa
Baptist Cancer Institute, Jacksonville
Orlando Health, Inc, Orlando
Local Institution, Bordeaux
Local Institution, Divinopolis
Southern Cancer Center, Mobile
Local Institution, Acapulco de Juárez
Kentucky Cancer Clinic, Hazard
Local Institution, Wuppertal
Gabrail Cancer Center, Canton
University Of Cincinnati, Cincinnati
Local Institution, Valencia
Local Institution, Meldola (fc)
Local Institution, Rimini
Siouxland Hematology-Oncology Assoc., Llp, Sioux City
University Of Iowa Hospitals And Clinics, Iowa City
Local Institution, Eschweiler
Local Institution, Tel Litwinsky
Local Institution, Siena
Local Institution, Bonn
Mayo Clinic, Rochester
Local Institution, Fortaleza
Edward Cancer Center, Naperville
University Of Chicago, Chicago
Mid-Illinois Hematology & Oncology Associates, Ltd, Normal
Local Institution, Cuernavaca
Cancer Care Specialists Of Central Illinois, Decatur
Local Institution, Clermont-Ferrand
Kansas City Veterans Affairs Medical Center, Kansas City
Local Institution, Tel Aviv
St Johns Medical Research Institute, Inc., Springfield
Hutchinson Clinic, Pa, Hutchinson
Local Institution, Mannheim
Local Institution, Beer Jacob
Local Institution, Puebla City
Highlands Oncology Group, P.A., Fayetteville
Center For Oncology Research & Treatment, P.A., Dallas
The Center For Cancer And Blood Disorders, Fort Worth
The University Of Texas Md Anderson Cancer Center, Houston
Northwest Cancer Center, Houston
Local Institution, Napoli
Local Institution, Curitiba
Local Institution, Curitiba
Local Institution, Beersheba
Huntsman Cancer Institute, Salt Lake City
Arizona Clinical Research Center, Inc., Tucson
Usc/Norris Comprehensive Cancer Center, Los Angeles
Prostate Oncology Specialists, Inc., Marina del Rey
Local Institution, Porto Alegre
Local Institution, Porto Alegre
Va San Diego Healthcare System, San Diego
Comprehensive Cancer Center, Palm Springs
Loma Linda University Cancer Center, Loma Linda
Marsha G. Fink, Md, Inc., Fountain Valley
Pacific Hematology Oncology Associates, San Francisco
Local Institution, Villejuif
Local Institution, Pointe à Pitre
Providence Portland Medical Center, Portland
Alaska Clinical Research Center, Llc, Anchorage
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Santiago de Compostela
Local Institution, Saint Petersburg
Local Institution, Obninsk
Local Institution, Romania
Local Institution, Suceava
Local Institution, Santiago
Local Institution, Santiago
Local Institution, Ijuí
Dana Farber Cancer Institute, Boston
Local Institution, Buenos Aires
Local Institution, Buenos Aires
Local Institution, Córdoba
Local Institution, Córdoba
Local Institution, Rosario
Local Institution, San Miguel de Tucumán
Local Institution, Mogi das Cruzes
Local Institution, São Paulo
Local Institution, São Paulo
Local Institution, Greenfield Park
Local Institution, Montreal
Local Institution, Temuco
Local Institution, Vi?a Del Mar
Local Institution, Santiago - Independencia
Local Institution, Montería
Local Institution, Bogotá
Local Institution, Dublin
Local Institution, Guadalajara
Local Institution, Brno
Local Institution, Hradec Králové
Local Institution, Liberec
Local Institution, Athens
Local Institution, Tallaght
Local Institution, Df
Local Institution, Mexico City
Local Institution, Amsterdam
Local Institution, Mb Amsterdam
Local Institution, Lima
Local Institution, Lima
Local Institution, Arequipa
Local Institution, Olsztyn
Ponce School Of Medicine, Ponce
Local Institution, Bucharest
Local Institution, Barcelona
Local Institution, Barcelona
Local Institution, Benidorm-alicante
Local Institution, Chelmsford
Local Institution, Cardiff
Local Institution, Manchester
Local Institution, Scunthorpe
Local Institution, Nottingham
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY